The Insulin-like Growth Factor Signaling Pathway as a Target for Treatment of Colorectal Carcinoma

被引：61

作者：

Ewing, Gideon P. ^{[1
]}

Goff, Laura W. ^{[1
]}

机构：

[1] Vanderbilt Univ, Dept Med, Div Hematol Oncol, Med Ctr, Nashville, TN 37232 USA

来源：

CLINICAL COLORECTAL CANCER | 2010年 / 9卷 / 04期

关键词：

IGF1; IGF2; Phosphatidylinositol; 3-kinase; Tyrosine kinase inhibitor; FACTOR-I RECEPTOR; CANCER-RISK; MONOCLONAL-ANTIBODY; FACTOR (IGF)-I; TUMOR-GROWTH; BINDING PROTEIN-3; EXPRESSION; INHIBITOR; KINASE; SERUM;

D O I：

10.3816/CCC.2010.n.032

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The insulin-like growth factors (IGFs), IGF1 and IGF2, are peptide hormones that bind to the insulin-like growth factor 1 receptor (IGF1R) and cause intracellular signaling that ultimately results in cellular growth and proliferation. Evidence from epidemiologic and preclinical studies suggests that IGF signaling may be of importance in the pathogenesis of colorectal cancer (CRC). In recent years, agents that target the IGF1R pathway have been developed. These agents are currently under evaluation for the treatment of CRC.

引用

页码：219 / 223

页数：5

共 47 条

[1]

Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines [J].

Adachi, Y ;

Lee, CT ;

Coffee, K ;

Yamagata, N ;

Ohm, JE ;

Park, KH ;

Dikov, MM ;

Nadaf, SR ;

Arteaga, CL ;

Carbone, DP .

GASTROENTEROLOGY, 2002, 123 (04) :1191-1204

[2]

ADACHI Y, 2007, 98 ANN M AM ASS CANC

[3]

[Anonymous], J CLIN ONCOL S

[4]

Acromegaly and cancer risk: a cohort study in Sweden and Denmark [J].

Baris, D ;

Gridley, G ;

Ron, E ;

Weiderpass, E ;

Mellemkjaer, L ;

Ekbom, A ;

Olsen, JH ;

Baron, JA ;

Fraumeni, JF .

CANCER CAUSES & CONTROL, 2002, 13 (05) :395-400

[5]

BLADT F, 2006, P AM ASS CANC RES, V47

[6]

Burtrum D, 2003, CANCER RES, V63, P8912

[7]

CARTLIDGE SA, 2009, 100 ANN M AM ASS CAN

[8]

EVALUATION OF ACROMEGALY BY RADIOIMMUNOASSAY OF SOMATOMEDIN-C [J].

CLEMMONS, DR ;

VANWYK, JJ ;

RIDGWAY, EC ;

KLIMAN, B ;

KJELLBERG, RN ;

UNDERWOOD, LE .

NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (21) :1138-1142

[9]

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871 [J].

Cohen, BD ;

Baker, DA ;

Soderstrom, C ;

Tkalcevic, G ;

Rossi, AM ;

Miller, PE ;

Tengowski, MW ;

Wang, F ;

Gualberto, A ;

Beebe, JS ;

Moyer, JD .

CLINICAL CANCER RESEARCH, 2005, 11 (05) :2063-2073

[10]

INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II - PEPTIDE, MESSENGER RIBONUCLEIC-ACID AND GENE STRUCTURES, SERUM, AND TISSUE CONCENTRATIONS [J].

DAUGHADAY, WH ;

ROTWEIN, P .

ENDOCRINE REVIEWS, 1989, 10 (01) :68-91

← 1 2 3 4 5 →